The role of Ketamine and Enantiomers in depression: comprehensive clinical review

Detalhes bibliográficos
Autor(a) principal: Rafael Henriques de Figueiredo
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/128786
Resumo: Major Depressive Disorder (MDD) is a common, distressful and disabling mental disorder. The currently available therapeutic agents have important limitations, as treatment-resistant depression (TRD) is experienced by 12-20% up to a third of patients. (R,S)-ketamine is the aryl-cyclo-hexylamine derivative synthetized from phencyclidine (PCP), composed by a mixture 1:1 of the (R) and (S) enantiomers. Clinical trials of (R,S)-ketamine, in all delivery formulations, and recently intranasal (S)-ketamine, showed good efficacy and safety profiles, though (R)-ketamine in preclinical trials regards great promise towards a better profile. This review covers the latest developments of ketamine (and it´s enantiomers) as a new-class antidepressant, such as clinical efficacy, safety and the role of electroconvulsive therapy (ECT). It also points the current limitations and directions towards the applicability of ketamine in routine clinical practice.
id RCAP_6a300cab9a9a3202c027c29089572f7b
oai_identifier_str oai:repositorio-aberto.up.pt:10216/128786
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The role of Ketamine and Enantiomers in depression: comprehensive clinical reviewMedicina clínicaClinical medicineMajor Depressive Disorder (MDD) is a common, distressful and disabling mental disorder. The currently available therapeutic agents have important limitations, as treatment-resistant depression (TRD) is experienced by 12-20% up to a third of patients. (R,S)-ketamine is the aryl-cyclo-hexylamine derivative synthetized from phencyclidine (PCP), composed by a mixture 1:1 of the (R) and (S) enantiomers. Clinical trials of (R,S)-ketamine, in all delivery formulations, and recently intranasal (S)-ketamine, showed good efficacy and safety profiles, though (R)-ketamine in preclinical trials regards great promise towards a better profile. This review covers the latest developments of ketamine (and it´s enantiomers) as a new-class antidepressant, such as clinical efficacy, safety and the role of electroconvulsive therapy (ECT). It also points the current limitations and directions towards the applicability of ketamine in routine clinical practice.2020-06-012020-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/128786TID:202617688engRafael Henriques de Figueiredoinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T13:54:03Zoai:repositorio-aberto.up.pt:10216/128786Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T23:50:11.619985Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The role of Ketamine and Enantiomers in depression: comprehensive clinical review
title The role of Ketamine and Enantiomers in depression: comprehensive clinical review
spellingShingle The role of Ketamine and Enantiomers in depression: comprehensive clinical review
Rafael Henriques de Figueiredo
Medicina clínica
Clinical medicine
title_short The role of Ketamine and Enantiomers in depression: comprehensive clinical review
title_full The role of Ketamine and Enantiomers in depression: comprehensive clinical review
title_fullStr The role of Ketamine and Enantiomers in depression: comprehensive clinical review
title_full_unstemmed The role of Ketamine and Enantiomers in depression: comprehensive clinical review
title_sort The role of Ketamine and Enantiomers in depression: comprehensive clinical review
author Rafael Henriques de Figueiredo
author_facet Rafael Henriques de Figueiredo
author_role author
dc.contributor.author.fl_str_mv Rafael Henriques de Figueiredo
dc.subject.por.fl_str_mv Medicina clínica
Clinical medicine
topic Medicina clínica
Clinical medicine
description Major Depressive Disorder (MDD) is a common, distressful and disabling mental disorder. The currently available therapeutic agents have important limitations, as treatment-resistant depression (TRD) is experienced by 12-20% up to a third of patients. (R,S)-ketamine is the aryl-cyclo-hexylamine derivative synthetized from phencyclidine (PCP), composed by a mixture 1:1 of the (R) and (S) enantiomers. Clinical trials of (R,S)-ketamine, in all delivery formulations, and recently intranasal (S)-ketamine, showed good efficacy and safety profiles, though (R)-ketamine in preclinical trials regards great promise towards a better profile. This review covers the latest developments of ketamine (and it´s enantiomers) as a new-class antidepressant, such as clinical efficacy, safety and the role of electroconvulsive therapy (ECT). It also points the current limitations and directions towards the applicability of ketamine in routine clinical practice.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-01
2020-06-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/128786
TID:202617688
url https://hdl.handle.net/10216/128786
identifier_str_mv TID:202617688
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135821159202816

Registros relacionados